Last reviewed · How we verify

NCT05028270

Treatment of Intraocular Retinoblastoma

Status unknown Last updated 1 June 2022
What this trial tests

trial testing Balloon technology;Microcatheter technology in Retinoblastoma in 1,600 participants. Status unknown.

Timeline
20 June 2022
Primary endpoint
1 October 2022
1 August 2023

Quick facts

Lead sponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,600
Start date20 June 2022
Primary completion1 October 2022
Estimated completion1 August 2023

Drugs / interventions tested

Conditions studied

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 1 to 18, any sex, with Retinoblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the effects of balloon technology and microcatheter technology on the eye protection rate of neuroblastoma

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Retinoblastoma

Currently open trials in the same condition.

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing